Cost-effectiveness analysis in heart disease, part III: Ischemia, congestive heart failure, and arrhythmias

Progress in Cardiovascular Diseases ◽

10.1016/s0033-0620(05)80017-9 ◽

1995 ◽

Vol 37 (5) ◽

pp. 307-346 ◽

Author(s):

Joel Kupersmith ◽

Margaret Holmes-Rovner ◽

Andrew Hogan ◽

David Rovner ◽

Joseph Gardiner

Keyword(s):

Heart Failure ◽

Congestive Heart Failure ◽

Heart Disease ◽

Cost Effectiveness ◽

Cost Effectiveness Analysis ◽

Effectiveness Analysis

Download Full-text

A cost-effectiveness analysis of enalapril maleate in the management of congestive heart failure in Australia

Australian and New Zealand Journal of Medicine ◽

10.1111/j.1445-5994.1996.tb02912.x ◽

1996 ◽

Vol 26 (1) ◽

pp. 89-95 ◽

Author(s):

J. R. G. Butler ◽

P. J. Fletcher

Keyword(s):

Heart Failure ◽

Congestive Heart Failure ◽

Cost Effectiveness ◽

Cost Effectiveness Analysis ◽

Enalapril Maleate ◽

Effectiveness Analysis

Download Full-text

Ferric carboxymaltose for the treatment of iron deficiency in heart failure: a multinational cost‐effectiveness analysis utilising AFFIRM‐AHF

European Journal of Heart Failure ◽

10.1002/ejhf.2270 ◽

2021 ◽

Author(s):

Phil McEwan ◽

Piotr Ponikowski ◽

Jason A. Davis ◽

Giuseppe Rosano ◽

Andrew J.S. Coats ◽

...

Keyword(s):

Heart Failure ◽

Cost Effectiveness ◽

Iron Deficiency ◽

Cost Effectiveness Analysis ◽

Ferric Carboxymaltose ◽

Effectiveness Analysis

Download Full-text

Cost–effectiveness analysis of genetic screening for the Taq1B polymorphism in the secondary prevention of coronary heart disease

Expert Review of Pharmacoeconomics & Outcomes Research ◽

10.1586/14737167.7.2.119 ◽

2007 ◽

Vol 7 (2) ◽

pp. 119-128 ◽

Author(s):

Linda K Kemp ◽

Christopher M Doran ◽

Theo Vos ◽

Wayne Hall

Keyword(s):

Coronary Heart Disease ◽

Heart Disease ◽

Cost Effectiveness ◽

Secondary Prevention ◽

Genetic Screening ◽

Cost Effectiveness Analysis ◽

Effectiveness Analysis

Download Full-text

Cost-Effectiveness Analysis of Sacubitril/Valsartan for the Treatment of Heart Failure with Reduced Ejection Fraction in the United States

Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy ◽

10.1002/phar.2108 ◽

2018 ◽

Vol 38 (5) ◽

pp. 520-530 ◽

Author(s):

Patrick M. Zueger ◽

Varun M. Kumar ◽

Rachel L. Harrington ◽

Gianna C. Rigoni ◽

Alicia Atwood ◽

...

Keyword(s):

United States ◽

Heart Failure ◽

Cost Effectiveness ◽

Ejection Fraction ◽

The United States ◽

Cost Effectiveness Analysis ◽

Reduced Ejection Fraction ◽

Effectiveness Analysis

Download Full-text

PMD10 COST EFFECTIVENESS ANALYSIS OF CARDIAC RESYNCHRONIZATION THERAPY FOR HEART FAILURE FROM A PUBLIC THIRD-PARTY PAYER PERSPECTIVE IN CHILE

Value in Health ◽

10.1016/j.jval.2019.04.1008 ◽

2019 ◽

Vol 22 ◽

pp. S217-S218

Author(s):

R. Bitran ◽

M. Russo ◽

D. May ◽

J. Valencia

Keyword(s):

Heart Failure ◽

Cost Effectiveness ◽

Cardiac Resynchronization Therapy ◽

Cost Effectiveness Analysis ◽

Third Party ◽

Cardiac Resynchronization ◽

Resynchronization Therapy ◽

Party Payer ◽

Effectiveness Analysis ◽

Payer Perspective

Download Full-text

Cost Effectiveness of Intensive Lipid-Lowering Treatment for Patients with Congestive Heart Failure and Coronary Heart Disease in the US

PharmacoEconomics ◽

10.2165/11531440-000000000-00000 ◽

2010 ◽

Vol 28 (1) ◽

pp. 47-60 ◽

Author(s):

Virginia M. Rosen ◽

Douglas C.A. Taylor ◽

Hemangi Parekh ◽

Ankur Pandya ◽

David Thompson ◽

...

Keyword(s):

Heart Failure ◽

Coronary Heart Disease ◽

Congestive Heart Failure ◽

Heart Disease ◽

Cost Effectiveness ◽

Lipid Lowering ◽

Download Full-text

The Cost-Effectiveness Analysis of Philips Motiva Telehealth System: A Comparison Between Home Telemonitoring, Nurse Telephone Support And Usual Care In Chronic Heart Failure

Value in Health ◽

10.1016/j.jval.2015.09.681 ◽

2015 ◽

Vol 18 (7) ◽

pp. A358 ◽

Author(s):

AS Grustam ◽

JL Severens ◽

D de Massari ◽

R Koymans ◽

H Vrijhoef

Keyword(s):

Heart Failure ◽

Cost Effectiveness ◽

Chronic Heart Failure ◽

Cost Effectiveness Analysis ◽

Telephone Support ◽

System A ◽

Effectiveness Analysis ◽

Home Telemonitoring ◽

Download Full-text

CV12 A COST-EFFECTIVENESS ANALYSIS OF ACE INHIBITOR TRANDOLAPRIL AS A PREVENTATIVE TREATMENT OF HEART-FAILURE PROGRESSION

Value in Health ◽

10.1016/s1098-3015(10)61617-8 ◽

2003 ◽

Vol 6 (6) ◽

pp. 631

Author(s):

H Lilliu ◽

C Le Pen ◽

K Lamiraud ◽

W Wittenberg

Keyword(s):

Heart Failure ◽

Cost Effectiveness ◽

Ace Inhibitor ◽

Cost Effectiveness Analysis ◽

Preventative Treatment ◽

Effectiveness Analysis ◽

Heart Failure Progression

Download Full-text

Cost-Effectiveness Analysis of Interventions for Congenital Heart Disease

Journal of Interventional Cardiology ◽

10.1111/j.1540-8183.1995.tb00585.x ◽

1995 ◽

Vol 8 (5) ◽

pp. 579-598 ◽

Author(s):

DARRYL T. GRAY

Keyword(s):

Congenital Heart Disease ◽

Heart Disease ◽

Cost Effectiveness ◽

Congenital Heart ◽

Cost Effectiveness Analysis ◽

Effectiveness Analysis

Download Full-text

Cost-Effectiveness Analysis of Serelaxin in Treatment of Patients with Acute Decompensated Heart Failure

Value in Health ◽

10.1016/j.jval.2016.09.1760 ◽

2016 ◽

Vol 19 (7) ◽

pp. A652

Author(s):

G Tolordava ◽

E Arinina ◽

R Yagudina ◽

A Kulikov

Keyword(s):

Heart Failure ◽

Cost Effectiveness ◽

Acute Decompensated Heart Failure ◽

Decompensated Heart Failure ◽

Cost Effectiveness Analysis ◽

Effectiveness Analysis

Download Full-text